Omówienie plakatu: COLUMBUS 7-Year Update: A Randomized, Open-Label, Phase 3 Trial of Encorafenib (Enco) + Binimetinib (Bini) vs Vemurafenib (Vemu) or Enco in Patients (Pts) (...)

Omówienie plakatu: COLUMBUS 7-Year Update: A Randomized, Open-Label, Phase 3 Trial of Encorafenib (Enco) + Binimetinib (Bini) vs Vemurafenib (Vemu) or Enco in Patients (Pts) with BRAF V600-Mutant Melanoma
prof. dr hab. n. med. Piotr Rutkowski